Clinical Trials Logo

Clinical Trial Summary

The APEX study is a multicenter, observational study designed to capture longitudinal follow-up of plasma biomarkers and cognitive and functional assessments on individuals who screen failed in the AHEAD study over approximately 4 years. Approximately 1000 participants will be enrolled across three groups: - Group A: Approximately 500 participants who are discordant on screening (plasma positive / Positron Emission Tomography (PET) negative), - Group B: Approximately 250 participants who are concordant on screening (plasma negative / PET negative), and - Group C: Approximately 250 participants selected from the individuals who previously screen failed prior to PET for the AHEAD study with oversampling of racial and ethnic populations underrepresented in Alzheimer's disease (AD) clinical trials. Primary Objectives: - Collect longitudinal cognitive and functional assessments and blood-based biomarker data - Evaluate, characterize, and compare the longitudinal cognitive and functional data between the three groups of participants - Compare longitudinal change across race and ethnicity, sex, and Apolipoprotein E (ApoE) status Exploratory Objectives: • Collect baseline amyloid PET on participants without prior amyloid PET data (Group C)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06416072
Study type Observational
Source University of Southern California
Contact
Status Enrolling by invitation
Phase
Start date September 21, 2023
Completion date June 2028

See also
  Status Clinical Trial Phase
Recruiting NCT06033066 - Financial Incentives and Recruitment to the APT Webstudy N/A
Recruiting NCT04851496 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
Recruiting NCT04846426 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension
Completed NCT04828122 - Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
Completed NCT02045056 - Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease Early Phase 1
Completed NCT03370744 - Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD
Completed NCT02963415 - Concurrent Aerobic Exercise and Virtual Reality Cognitive Training N/A
Active, not recruiting NCT04004767 - TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting NCT04468659 - AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Phase 3
Recruiting NCT04937959 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension
Completed NCT04928976 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping
Recruiting NCT04951284 - Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension